Literature DB >> 20401918

Long-term clinical outcome of pelvic exenteration in patients with advanced gynecological malignancies.

Christina Fotopoulou1, Ulf Neumann, Robert Kraetschell, Joerg C Schefold, Henning Weidemann, Werner Lichtenegger, Jalid Sehouli.   

Abstract

BACKGROUND AND OBJECTIVES: We evaluated the outcome of pelvic exenteration in women with locally advanced primary or recurrent gynecological malignancies.
METHODS: All pelvic exenteration procedures performed between 01/2003 and 06/2009 were evaluated. Extent of surgical radicality, operative techniques, and outcome were evaluated. Kaplan-Meier curves were calculated for Overall (OS) and progression-free survival (PFS).
RESULTS: Forty-seven patients (median age: 52.5 years) were evaluated. Ten of 47 patients (21.3%) had a primary and 37(78.7%) a relapsed cancer. Most common (80.8%) site of origin was the cervix. Patients (80.8%) had undergone previous pelvic irradiation. A total exenteration was performed in 32/47 patients (68%). A complete tumor resection was obtained in 23 patients (49%). Thirty-three patients (70.2%) had at least one major complication, including ileus (8.5%), intestinal-fistula (29.8%), ureteral anastomotic insufficiency (6.4%), abscess (6.4%), and cardiothrombotic events (23.4%). At a median follow-up of 7 months (range: 1-42), 22/47 patients (46.8%) died and 22/47 (46.8%) experienced a relapse. Median OS was 4 months (range: 0.1-16) and 22 months (range: 6-42) for patients with versus without postoperative tumor residuals, respectively (P = 0.0006), while median PFS was 4 months (range:0.1-16) versus 12 months (range: 6-42) (P < 0.0001).
CONCLUSIONS: Radical pelvic exenteration due to advanced pelvic malignancies may be associated with a high morbidity. Complete tumor resection is associated with a significantly higher overall and PFS. (c) 2010 Wiley-Liss, Inc.

Entities:  

Mesh:

Year:  2010        PMID: 20401918     DOI: 10.1002/jso.21518

Source DB:  PubMed          Journal:  J Surg Oncol        ISSN: 0022-4790            Impact factor:   3.454


  18 in total

1.  Pelvic Exenteration Put into Therapeutical and Palliative Perspective: It Is Worth to Try.

Authors:  Iosifina Karmaniolou; Nikolaos Arkadopoulos; Pantelis Vassiliou; Constantinos Nastos; Dionysios Dellaportas; Argyris Siatelis; Theodosis Theodosopoulos; Antonios Vezakis; Stavros Parasyris; Andreas Polydorou; Vassilios Smyrniotis
Journal:  Indian J Surg Oncol       Date:  2018-07-20

2.  Outcomes of a bladder preservation technique in female patients undergoing pelvic exenteration surgery for advanced gynaecological tumours.

Authors:  Bernhard Liedl; Wael Y Khoder; Brigitte Ruhdorfer-Metz; Christian G Stief; Raphaela Waidelich
Journal:  Int Urogynecol J       Date:  2014-03-15       Impact factor: 2.894

3.  The effect of body mass index on surgical outcomes and survival following pelvic exenteration.

Authors:  David A Iglesias; Shannon N Westin; Vijayashri Rallapalli; Marilyn Huang; Bryan Fellman; Diana Urbauer; Michael Frumovitz; Pedro T Ramirez; Pamela T Soliman
Journal:  Gynecol Oncol       Date:  2012-01-16       Impact factor: 5.482

4.  Which operation is described?

Authors:  Radek Chvatal; Dietmar Haas; Cemil Yaman; Peter Oppelt
Journal:  J Turk Ger Gynecol Assoc       Date:  2011-06-01

5.  Pelvic exenteration in gynecologic oncology: a single institution study over 20 years.

Authors:  T Benn; R A Brooks; Q Zhang; M A Powell; P H Thaker; D G Mutch; I Zighelboim
Journal:  Gynecol Oncol       Date:  2011-03-27       Impact factor: 5.482

6.  Factors affecting hospital length of stay following pelvic exenteration surgery.

Authors:  Ying Guo; Eugene Chang; Mehtap Bozkurt; Minjeong Park; Diane Liu; Jack B Fu
Journal:  J Surg Oncol       Date:  2017-10-16       Impact factor: 3.454

7.  Local Radiotherapy or Chemotherapy for Oligo-recurrent Cervical Cancer in Patients With Prior Pelvic Irradiation.

Authors:  Kazuma Kobayashi; Naoya Murakami; Kana Takahashi; Koji Inaba; Ryuji Hamamoto; Jun Itami
Journal:  In Vivo       Date:  2019 Sep-Oct       Impact factor: 2.155

8.  Clinical outcome of pelvic exenteration in patients with advanced or recurrent uterine cervical cancer.

Authors:  Sota Tanaka; Satoru Nagase; Michiko Kaiho-Sakuma; Tomoyuki Nagai; Hiroki Kurosawa; Masafumi Toyoshima; Hideki Tokunaga; Takeo Otsuki; Hiroki Utsunomiya; Tadao Takano; Hitoshi Niikura; Kiyoshi Ito; Nobuo Yaegashi
Journal:  Int J Clin Oncol       Date:  2013-02-13       Impact factor: 3.402

9.  Pelvic exenteration: impact of age on surgical and oncologic outcomes.

Authors:  Marilyn Huang; David A Iglesias; Shannon N Westin; Bryan Fellman; Diana Urbauer; Kathleen M Schmeler; Michael Frumovitz; Pedro T Ramirez; Pamela T Soliman
Journal:  Gynecol Oncol       Date:  2013-11-18       Impact factor: 5.482

10.  Total pelvic exenteration for gynecologic malignancies.

Authors:  Elisabeth J Diver; J Alejandro Rauh-Hain; Marcela G Del Carmen
Journal:  Int J Surg Oncol       Date:  2012-06-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.